Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

TY - JOUR

T1 - Systemic anticancer therapy-induced peripheral and central neurotoxicity

T2 - ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

AU - ESMO Guidelines Committee

AU - EONS Education Working Group

AU - EANO Guideline Committee

AU - Jordan, B.

AU - Margulies, A.

AU - Cardoso, F.

AU - Cavaletti, G.

AU - Haugnes, H. S.

AU - Jahn, P.

AU - Le Rhun, E.

AU - Preusser, M.

AU - Scotté, F.

AU - Taphoorn, M. J.B.

AU - Jordan, K.

N1 - Funding Information: BJ has reported advisory board and/or honoraria for presentations for Alexion Pharmaceuticals, Temmler (Hormosan Pharma), Novartis, Biomarin, Merz Pharmaceuticals, Ipsen Pharma and Allergan; FC has reported consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME, Roche, Sanofi, Seattle Genetics and Teva; GC has reported financial interests, honoraria for speaker, consultancy or advisory role and/or institutional research funding from Toray, Disarm, Helsinn, PledPharma, Mundipharma, Kedrion and Chiesi; PJ has reported travel support from Helsinn, consulting or advisory role for Bristol-Myers Squibb, Chugai, Norgine, Helsinn and Clinigen and research grant from Chugai; ELR has received research grants from Mundipharma and Amgen, honoraria for lectures or advisory board from Tocagen, AbbVie, Daiichi Sankyo, Mundipharma and Novartis; MP has received honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca, AbbVie, Lilly, MEDahead, Daiichi Sankyo, Merck Sharp & Dohme and has reported research funding from Bristol-Myers Squibb, Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche; FS has reported financial interests, honoraria for speaker, consultancy or advisory role, royalties, direct research funding from Tesaro, Helsinn, Vifor, Merck Sharp & Dohme, Roche, Amgen, Pierre Fabre Oncology, Pfizer, Leo Pharma, Arrow and Bristol-Myers Squibb; KJ has reported financial interests, honoraria for speaker, consultancy or advisory role, royalties and direct research funding from Merck Sharp & Dohme, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, POMME-med, PharmaMar, priME Oncology and Onko Solutions; all remaining authors have declared no conflicts of interest. Funding Information: The ESMO Guidelines Committee thank the ESMO, EONS and EANO Faculties and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition for their review. The authors thank Dr. Camilla Leithold for her editorial assistance. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. BJ has reported advisory board and/or honoraria for presentations for Alexion Pharmaceuticals, Temmler (Hormosan Pharma), Novartis, Biomarin, Merz Pharmaceuticals, Ipsen Pharma and Allergan; FC has reported consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME, Roche, Sanofi, Seattle Genetics and Teva; GC has reported financial interests, honoraria for speaker, consultancy or advisory role and/or institutional research funding from Toray, Disarm, Helsinn, PledPharma, Mundipharma, Kedrion and Chiesi; PJ has reported travel support from Helsinn, consulting or advisory role for Bristol-Myers Squibb, Chugai, Norgine, Helsinn and Clinigen and research grant from Chugai; ELR has received research grants from Mundipharma and Amgen, honoraria for lectures or advisory board from Tocagen, AbbVie, Daiichi Sankyo, Mundipharma and Novartis; MP has received honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca, AbbVie, Lilly, MEDahead, Daiichi Sankyo, Merck Sharp & Dohme and has reported research funding from Bristol-Myers Squibb, B?hringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche; FS has reported financial interests, honoraria for speaker, consultancy or advisory role, royalties, direct research funding from Tesaro, Helsinn, Vifor, Merck Sharp & Dohme, Roche, Amgen, Pierre Fabre Oncology, Pfizer, Leo Pharma, Arrow and Bristol-Myers Squibb; KJ has reported financial interests, honoraria for speaker, consultancy or advisory role, royalties and direct research funding from Merck Sharp & Dohme, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, POMME-med, PharmaMar, priME Oncology and Onko Solutions; all remaining authors have declared no conflicts of interest.

PY - 2020/10/1

Y1 - 2020/10/1

KW - CIPN

KW - Clinical Practice Guidelines

KW - central neuropathy

KW - diagnosis

KW - peripheral neurotoxicity

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85090061697&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.07.003

DO - 10.1016/j.annonc.2020.07.003

M3 - Article

C2 - 32739407

AN - SCOPUS:85090061697

SN - 0923-7534

VL - 31

SP - 1306

EP - 1319

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -